4.7 Article

Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions

Journal

ACTA PHARMACOLOGICA SINICA
Volume 40, Issue 10, Pages 1351-1363

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41401-019-0273-1

Keywords

ginsenoside; cytochrome P450 3A; organic anion-transporting polypeptide 1B3; herbal medicine-drug interactions; XueShuanTong; Panax notoginseng

Funding

  1. National Key R&D Program of China [2018YFC1704500]
  2. National Science and Technology Major Project of China Key New Drug Creation and Manufacturing Program [2012ZX09101201-005, 2017ZX09301012-006]
  3. National Natural Science Foundation of China [81673582]
  4. Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12050306]
  5. National Basic Research Program of China [2012CB518403]

Ask authors/readers for more resources

XueShuanTong, a lyophilized extract of Panax notoginseng roots (Sanqi) for intravenous administration, is extensively used as add-on therapy in the treatment of ischemic heart and cerebrovascular diseases and comprises therapeutically active ginsenosides. Potential for XueShuanTong-drug interactions was determined; the investigation focused on cytochrome P450 (CYP)3A induction and organic anion-transporting polypeptide (OATP)1B inhibition. Ginsenosides considerably bioavailable for drug interactions were identified by dosing XueShuanTong in human subjects and their interaction-related pharmacokinetics were determined. The CYP3A induction potential was determined by repeatedly dosing XueShuanTong for 15 days in human subjects and by treating cryopreserved human hepatocytes with circulating ginsenosides; midazolam served as a probe substrate. Joint inhibition of OATP1B by XueShuanTong ginsenosides was assessed in vitro, and the data were processed using the Chou-Talalay method. Samples were analyzed by liquid chromatography/mass spectrometry. Ginsenosides Rb-1, Rd, and Rg(1) and notoginsenoside R-1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb-1 and Rd, long terminal half-lives (32-57 and 58-307 h, respectively) and low unbound fractions in plasma (0.8%-2.9% and 0.4%-3.0%, respectively). Dosing XueShuanTong did not induce CYP3A. Based on the pharmacokinetics and inhibitory potency of the ginsenosides, XueShuanTong was predicted to have high potential for OATP1B3-mediated drug interactions (attributed chiefly to ginsenoside Rb1) suggesting the need for further model-based determination of the interaction potential for XueShuanTong and, if necessary, a clinical drug interaction study. Increased awareness of ginsenosides' pharmacokinetics and XueShuanTong-drug interaction potential will help ensure the safe use of XueShuanTong and coadministered synthetic drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available